R&G PharmaStudies Co., Ltd. — Investor Relations & Filings
R&G PharmaStudies Co., Ltd. is a comprehensive Contract Research Organization (CRO) providing full-service clinical research solutions to the global pharmaceutical and biotechnology sectors. The company specializes in managing Phase I through IV clinical trials, offering a broad suite of services including clinical trial operation, site management, medical writing, regulatory affairs, and pharmacovigilance. Additionally, R&G provides specialized expertise in data management and biostatistics, ensuring high-quality data integrity and compliance with international standards such as NMPA, FDA, and EMA. With an extensive network of clinical trial sites and a focus on diverse therapeutic areas, the company facilitates efficient drug development processes. R&G is recognized for its integrated approach to clinical development, supporting clients from early-stage research through to post-marketing surveillance and bioequivalence studies.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2026年一季度报告 | 2026-04-27 | Chinese | |
| 第五届董事会第二十次会议决议公告 | 2026-04-27 | Chinese | |
| 关于持股5%以上股东及特定股东减持股份触及1%的整数倍暨减持计划提前实施完成的公告 | 2026-04-21 | Chinese | |
| 中国国际金融股份有限公司关于诺思格(北京)医药科技股份有限公司2025年度持续督导跟踪报告 | 2026-04-14 | Chinese | |
| 中国国际金融股份有限公司关于诺思格(北京)医药科技股份有限公司持续督导保荐总结报告书 | 2026-04-10 | Chinese | |
| 简式权益变动报告书 | 2026-04-03 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 38627195 | 2026年一季度报告 | 2026-04-27 | Chinese | ||
| 38627177 | 第五届董事会第二十次会议决议公告 | 2026-04-27 | Chinese | ||
| 38627149 | 关于持股5%以上股东及特定股东减持股份触及1%的整数倍暨减持计划提前实施完成的公告 | 2026-04-21 | Chinese | ||
| 38627146 | 中国国际金融股份有限公司关于诺思格(北京)医药科技股份有限公司2025年度持续督导跟踪报告 | 2026-04-14 | Chinese | ||
| 38627133 | 中国国际金融股份有限公司关于诺思格(北京)医药科技股份有限公司持续督导保荐总结报告书 | 2026-04-10 | Chinese | ||
| 38627113 | 简式权益变动报告书 | 2026-04-03 | Chinese | ||
| 38627111 | 关于持股5%以上股东及特定股东权益变动比例触及5%整数倍暨披露简式权益变动报告书的提示性公告 | 2026-04-03 | Chinese | ||
| 38627108 | 2025年度独立董事述职报告(孙雯) | 2026-03-27 | Chinese | ||
| 38627089 | 关于诺思格(北京)医药科技股份有限公司2025年度募集资金存放与实际使用情况鉴证报告 | 2026-03-27 | Chinese | ||
| 38627058 | 关于会计师事务所2025年度履职情况的评估报告 | 2026-03-27 | Chinese | ||
| 38627043 | 2025年年度报告 | 2026-03-27 | Chinese | ||
| 38627036 | 2025年度内部控制自我评价报告 | 2026-03-27 | Chinese | ||
| 38626939 | 2025年度独立董事述职报告(石浩海) | 2026-03-27 | Chinese | ||
| 38626921 | 董事、高级管理人员薪酬管理办法(2026年3月) | 2026-03-27 | Chinese | ||
| 38626887 | 中国国际金融股份有限公司关于诺思格(北京)医药科技股份有限公司2025年度募集资金存放与实际使用情况的核查意见 | 2026-03-27 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
R&G PharmaStudies Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56248/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56248 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56248 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56248 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56248}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for R&G PharmaStudies Co., Ltd. (id: 56248)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.